4//SEC Filing
Janda Kim 4
Accession 0001209191-21-057957
CIK 0000850261other
Filed
Sep 27, 8:00 PM ET
Accepted
Sep 28, 5:37 PM ET
Size
13.3 KB
Accession
0001209191-21-057957
Insider Transaction Report
Form 4
Janda Kim
Director
Transactions
- Exercise/Conversion
Common Stock
2021-09-27$1.80/sh+35,000$63,000→ 38,000 total - Exercise/Conversion
Common Stock
2021-09-27$3.57/sh+7,357$26,264→ 45,357 total - Exercise/Conversion
Stock Options
2021-09-27−7,357→ 27,643 totalExercise: $3.57Exp: 2028-11-26→ Common Stock (7,357 underlying) - Sale
Common Stock
2021-09-27$8.02/sh−42,357$339,720→ 3,000 total - Exercise/Conversion
Stock Options
2021-09-27−35,000→ 0 totalExercise: $1.80Exp: 2027-09-15→ Common Stock (35,000 underlying)
Footnotes (4)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.00 to $8.03, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price.
- [F3]1/12 of the original number of shares subject to this option vested and became exercisable on October 15, 2017 and 1/12 of the original number of shares subject to the option vested following each one month of service thereafter.
- [F4]1/12 of the original number of shares subject to this option vested and became exercisable on December 26, 2018 and 1/12 of the original number of shares subject to the option vested following each one month of service thereafter.
Documents
Issuer
Sorrento Therapeutics, Inc.
CIK 0000850261
Entity typeother
Related Parties
1- filerCIK 0001518466
Filing Metadata
- Form type
- 4
- Filed
- Sep 27, 8:00 PM ET
- Accepted
- Sep 28, 5:37 PM ET
- Size
- 13.3 KB